Verrica Pharmaceuticals, Inc. is hoping to tap a potentially multibillion-dollar market for the most common form of cancer in the US, basal cell carcinoma (BCC), with positive Phase II data for its immunotherapy VP-315.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?